The firm recently released two droplet digital PCR-based assays that can characterize edits generated by CRISPR-Cas9 or other genome editing tools.
The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.
Sales in the life science segment grew 5 percent due in part to sales of the firm's Digital Droplet PCR system and reagents.
The legal battle began last fall when LabCorp subsidiary Esoterix and Johns Hopkins University sued Myriad alleging infringement of four patents.
The firm's topline performance for the full year was also higher than previous guidance provided by the company and analyst estimates.
A jury in Northern California has found that Sanford Wadler was wrongfully terminated and awarded him back pay and punitive damages.
Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Terms of the deal have not been disclosed, but the firms expect to finalize the acquisition in the first quarter of 2017.
Systems will ship in early February and include droplet-based library prep and analytics functionalities.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.